LSD

Drug science is all about timing. You can either take a preexisting molecule, which has benefits for alternative indications rather than what it’s originally on shelves for, and you…
Mind Medicine (MNMD.Q, MMED.NE) announced that they have agreed to partner with Forian (FORA.Q), who provide evidence-based support for clinical and commercial decision making. Forian and MindMed will collaborate…
MindMed (MNMD.Q) will participate and assist in the financing of the Digital Medicine Society’s (DiMe) Digital Health Measurement Collaborative Community (DATAcc) in the development of best practices, and the…
Bioasis Technologies (BTI.V) announced they are entering into a research collaboration with Oxyrane UK. As Equity Guru previously reported, Bioasis is developing the xB³ platform, which aims penetrate the…
Mind Medicine (MNMD.Q) announced the addition of Dr. Peter Bergethon to their Scientific Advisory Board. Bergethon is a “world-leading” expert in neurology, digital medicine, and central nervous system (CNS)…
Mind Medicine (MMED.NE) announced the publication of the first pharmacogenetic data on LSD to help personalize dosing. The study results from a pooled secondary analysis of four Phase I…
Core One Labs (COOL.C) subsidiary, Vocan Biotechnologies, and the University of British Columbia (UBC), came to terms on a collaborative research agreement today, according to a press release. The…
Algernon Pharmaceuticals (AGN.C) has established a clinical trial program to treat stroke that uses DMT, or (N-dimethyltryptamine) today, according to a press release. The company decided to take a…
Mind Medicine (MMED.E) announced earlier this week their intention to conduct a randomized placebo-controlled study using LSD to evaluate certain health and cognitive effects according to a press release….
The notion of magic mushroom market offering after the legalization of cannabis has been floated time and again since long before cannabis legalization was even on the table. It…